March 24, 2020 / 6:28 AM / 14 days ago

BRIEF-Novartis says Zolgensma helped SMA patients up to 5 years after dosing

March 24 (Reuters) - Novartis AG says:

* ZOLGENSMA DATA SHOWS RAPID, SIGNIFICANT, CLINICALLY MEANINGFUL BENEFIT IN SMA INCLUDING PROLONGED EVENT-FREE SURVIVAL, MOTOR MILESTONE ACHIEVEMENT AND DURABILITY NOW UP TO 5 YEARS POST-DOSING Further company coverage: (Reporting by John Miller)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below